Search
CRISPR Therapeutics AG
CRSPAdd to Watchlist
53.550USD
-0.440-0.81%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
5.16BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.81%
5 Days
+0.87%
1 Month
+6.33%
6 Months
-5.57%
Year to Date
+2.12%
1 Year
+14.47%
Key Figures
54.150Open
55.480High
1.41MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.47%Turnover Ratio
53.990Prev. Close
53.350Low
59.53MTurnover
LossP/E Static
2.67P/B
0.00%Div Yield TTM
-23.24%ROA
78.48052wk High
0.90Volume Ratio
-366.25MNet Profit
95.89MShares
-6.1650EPS TTM
1.78Beta
-31.21%ROE
30.04052wk Low
3.94%Amplitude
100.00%Gross Margin
5.16BMarket Cap
1.30Reward/Risk
3.57%Risk Rate
TradingKey Stock Score of CRISPR Therapeutics AG
Currency: USD Updated: 2026-06-24Key Insights
CRISPR Therapeutics AG's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 149 out of 388 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 80.67.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CRISPR Therapeutics AG's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
CRISPR Therapeutics AG Highlights
StrengthsRisks
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.51M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.51M.
Overvalued
The company’s latest PE is -8.69, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 75.38M shares, decreasing 7.26% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 10.05M shares of this stock.
Analyst Rating
Based on
26
analysts
Buy
Current Rating
80.672
Target Price
+49.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CRISPR Therapeutics AG News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CRISPR Therapeutics AG Info
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Ticker SymbolCRSP
CompanyCRISPR Therapeutics AG
CEOKulkarni (Samarth)
Websitehttps://crisprtx.com/
Related Instruments
+0.90%
+0.82%
+0.08%
-0.14%
+0.88%
+0.83%
+1.27%
-0.02%
+0.09%
-2.71%
+1.45%
-0.89%
-1.86%
-0.65%
+0.41%
0.00%
+0.87%
+1.80%
-0.11%
-0.76%Popular Instruments
FAQs
What is the current price of CRISPR Therapeutics AG (CRSP)?
The current price of CRISPR Therapeutics AG (CRSP) is 53.55.
What is the symbol of CRISPR Therapeutics AG?
The ticker symbol of CRISPR Therapeutics AG is CRSP.
What is the 52-week high of CRISPR Therapeutics AG?
The 52-week high of CRISPR Therapeutics AG is 78.48.
What is the 52-week low of CRISPR Therapeutics AG?
The 52-week low of CRISPR Therapeutics AG is 30.04.
What is the market capitalization of CRISPR Therapeutics AG?
The market capitalization of CRISPR Therapeutics AG is 5.14B.
Is CRISPR Therapeutics AG (CRSP) currently rated as Buy, Hold, or Sell?
According to analysts, CRISPR Therapeutics AG (CRSP) has an overall rating of Buy, with a price target of 80.67.
What is the Earnings Per Share (EPS TTM) of CRISPR Therapeutics AG (CRSP)?
The Earnings Per Share (EPS TTM) of CRISPR Therapeutics AG (CRSP) is -6.47.
